General
Preferred name
PIOGLITAZONE
Synonyms
PIOGLITAZONE HYDROCHLORIDE ()
U 72107 ()
U-72107E ()
Pioglitazone (Actos) ()
Actos ()
Pioglitazone (hydrochloride) ()
pioglitazone hydrochloride112529-15-4 ()
U 72107A ()
AD 4833 ()
Pioglitazone HCl ()
Pioglitazone (AD-4833) ()
AD-4833, U-72107E ()
Pioglitazone potassium salt ()
Pioglitazone (as hydrochloride) ()
Piomed ()
Diabiom ()
Glizofar ()
NSC-758876 ()
Glidipion ()
STR-001 ()
U-72107A ()
AD-4833 ()
Glustin ()
U-72107 ()
Zactos ()
Duetact ()
Pioglitazone (potassium salt) ()
Pioglitazone-d4 ()
P&D ID
PD009788
CAS
111025-46-8
105355-27-9
112529-15-4
1266523-09-4
1134163-29-3
Tags
natural product
drug
available
Approved by
FDA
First approval
1999
Drug Status
investigational
approved
withdrawn
Drug indication
Diabetic complication
Obesity
Antidiabetic
Type-2 diabetes
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Pioglitazone enhances cellular responsiveness to insulin, increases insulin-dependent glucose disposal and improves hepatic sensitivity to insulin. In patients with type 2 diabetes, the decreased insulin resistance produced by pioglitazone results in lower plasma glucose concentrations, lower plasma insulin concentrations, and lower HbA1c values [FDA Label]; ; Additionally, patients treated with pioglitazone had mean decreases in serum triglycerides, mean increases in HDL cholesterol, and no consistent mean changes in LDL and total cholesterol [FDA Label].
DESCRIPTION Pioglitazone is a thiazolidinedione class antihyperglycemic drug. (GtoPdb)
DESCRIPTION Selective PPARgamma agonist; antidiabetic agent (Tocriscreen Plus)
DESCRIPTION Selective, high affinity PPARalpha agonist (Tocris Bioactive Compound Library)
DESCRIPTION Pioglitazone is a PPARγ agonist (EC50 = ~500-600 nM) with selectivity for PPARγ over PPARα. It has been used as a medication indicated for the treatment of diabetes mellitus type 2, It works by lowering insulin resistance thus reducing glucose level. (BOC Sciences Bioactive Compounds)
Cell lines
4
Organisms
0
Compound Sets
36
AdooQ Bioactive Compound Library
A11680
Axon Medchem Screening Library
3255
BOC Sciences Bioactive Compounds
pioglitazone-potassium-salt-cas-1266523-09-4-8723
Cayman Chemical Bioactives
22263
18259
71745
10028
ChEMBL Approved Drugs
CHEMBL1715
CHEMBL595
ChEMBL Drugs
CHEMBL1715
CHEMBL595
Concise Guide to Pharmacology 2017/18
2694
Concise Guide to Pharmacology 2019/20
2694
Concise Guide to Pharmacology 2021/22
2694
Concise Guide to Pharmacology 2023/24
2694
DrugBank
DB01132
DrugBank Approved Drugs
DB01132
DrugCentral
2179
DrugCentral Approved Drugs
2179
DrugMAP
DMKJ485
DrugMAP Approved Drugs
DMKJ485
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101571
Guide to Pharmacology
2694
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL595
MedChem Express Bioactive Compound Library
HY-14601
HY-13956
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
JQT35NPK6C
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
NURSA ligand set
nursa/index.jsf?doi=10.1621%2FKQK3B7FMLX
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
pioglitazone-hydrochloride-actos
pioglitazone
TargetMol Bioactive Compound Library
T0214
The Spectrum Collection
Tocris Bioactive Compound Library
4124
Tocriscreen Plus
4124
Withdrawn 2.0
w262
External IDs
84
Properties
(calculated by RDKit )
Molecular Weight
356.12
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
7
Ring Count
3
Aromatic Ring Count
2
cLogP
3.16
TPSA
68.29
Fraction CSP3
0.32
Chiral centers
1.0
Largest ring
6.0
QED
0.83
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Nuclear Receptors
Pathway
Metabolism
DNA Damage/DNA Repair
Apoptosis
Cell Cycle/DNA Damage
Vitamin D Related/Nuclear Receptor
Target
PPAR
PPAR? agonist
Ferroptosis
Ferroptosis,P450 (e.g. CYP17),PPAR
Primary Target
PPAR?
MOA
PPAR agonist
Agonist
Insulin Sensitizers
PPARgamma Agonists
Member status
member
ATC
A10BG03
Toxicity type
carcinogenicity
Therapeutic Indication
Antidiabetic
Therapeutic Class
Metabolic Disorders
Hypoglycemic Agents
Source data